BioCentury | Oct 6, 2018
Finance

Large cap comeback

...of its value after announcing in early September that it will discontinue development of the ELAD system...
BioCentury | Sep 13, 2018
Clinical News

Vital discontinues ELAD system after Phase III miss

...ELAD system and explore strategic options. The move comes after newly released data showed that the ELAD system...
...91 vs. SOC alone. Based on the data, Vital said it does not believe the ELAD system...
...ELAD (see "ELAD System: Phase III Data" ). Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Product: ELAD system...
BioCentury | Sep 12, 2018
Clinical News

Vital falls on discontinuation of ELAD system

...ELAD system and explore strategic options. The move comes after newly released data showed that the ELAD system...
...91 vs. SOC alone. Based on the data, Vital said it does not believe the ELAD system...
...serum creatinine level of <1.3 mg/dL and bilirubin level of ≥16 mg/dL. In 2015, the ELAD system...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation MAA approval 2H18 Vital Therapies Inc. (NASDAQ:VTL) ELAD system...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...in CMV-seropositive hematopoietic stem cell transplant recipients Ph III data 1Q18 Vital Therapies Inc. (NASDAQ:VTL) ELAD system...
BioCentury | May 30, 2016
Clinical News

ELAD system: Phase III started

...Vital began the open-label, international Phase III VTL-308 trial to compare the ELAD system in combination with...
...mg/dL and bilirubin level of >=16 mg/dL. Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Product: ELAD system...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...the other end of the spectrum, Vital Therapies Inc. crumbled 81% last quarter when its ELAD system...
...II trial to reduce neuropathic pain resulting from spinal cord injury Vital Therapies Inc. (NASDAQ:VTL) ELAD system...
BioCentury | Sep 7, 2015
Analyst Picks & Changes

Analyst picks & changes

...from outperform) -2% $3.35 Xu also lowered her target to $6 from $40 after Vital's ELAD system...
BioCentury | Sep 7, 2015
Clinical News

ELAD system: Phase III data

...the open-label, international Phase III VTI-208 trial in 203 patients with AILD showed that the ELAD system...
...0.575 for the ELAD system plus SOC vs. SOC alone (p=0.077). In the 120-patient subset, the ELAD system...
...for the ELAD system plus SOC vs. SOC alone (p=0.167). Additionally in the 101-patient cohort, the ELAD system...
BioCentury | Aug 22, 2015
Clinical News

Vital's ELAD misses in liver failure Phase III

...Inc. (NASDAQ:VTL) plummeted $13.33 (75%) to $4.35 in early after-hours trading on Friday after its ELAD system...
Items per page:
1 - 10 of 14